 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || PIT565 / Novartis
Trial completion date, Trial primary completion date: Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies (clinicaltrials.gov) - Nov 27, 2023
P1, N=140, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Feb 2026 --> Jun 2028 | Trial primary completion date: Feb 2025 --> Jun 2027
- PIT565 / Novartis
A Phase 1 Study of PIT565, a First-in-Class, Anti-CD3, Anti-CD19, Anti-CD2 Trispecific Antibody in Patients with Relapsed and/or Refractory B-Cell Malignancies (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_4029;
P1
The dose escalation phase is guided by an adaptive Bayesian logistic regression model following the escalation with overdose control principle. The MTD and/or RD are further explored during the dose-expansion phase.
- PIT565 / Novartis
A First-in-Class Anti-CD19, Anti-CD3, Anti-CD2 Trispecific Antibody (PIT565) for the Treatment of B Cell Malignancies () - Jun 15, 2023 - Abstract #IOSUMMITEUROPE2023IO_SUMMIT_EUROPE_146;
- PIT565 / Novartis
POSTER HIGHLIGHT: A First-in-Class Anti-CD19, Anti-CD3, Anti-CD2 Trispecific Antibody (PIT565) for the Treatment of B Cell Malignancies () - Jun 15, 2023 - Abstract #IOSUMMITEUROPE2023IO_SUMMIT_EUROPE_91;
- || PIT565 / Novartis
Trial completion date, Trial primary completion date: Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies (clinicaltrials.gov) - Feb 27, 2023
P1, N=140, Recruiting, Sponsor: Novartis Pharmaceuticals
The MTD and/or RD are further explored during the dose-expansion phase. Trial completion date: Aug 2025 --> Feb 2026 | Trial primary completion date: Aug 2024 --> Feb 2025
- PIT565 / Novartis
PIT565, a First-in-Class Anti-CD19, Anti-CD3, Anti-CD2 Trispecific Antibody for the Treatment of B Cell Malignancies (Hall D (Ernest N. Morial Convention Center)) - Nov 4, 2022 - Abstract #ASH2022ASH_2197;
P1
Taken together, the findings from the preclinical studies suggest that PIT565 may achieve deeper and more durable responses compared to competitor CD3 bispecifics. First-in-human trial of PIT565 (NCT05397496) has been initiated and will be conducted in patients who are diagnosed with relapsed and/or refractory adult NHL after receiving two or more lines of chemotherapy and patients with relapsed and/or refractory B-ALL.
- ||| PIT565 / Novartis
Enrollment open: Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies (clinicaltrials.gov) - Sep 14, 2022
P1, N=140, Recruiting, Sponsor: Novartis Pharmaceuticals
First-in-human trial of PIT565 (NCT05397496) has been initiated and will be conducted in patients who are diagnosed with relapsed and/or refractory adult NHL after receiving two or more lines of chemotherapy and patients with relapsed and/or refractory B-ALL. Not yet recruiting --> Recruiting
- ||| PIT565 / Novartis
New P1 trial: Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies (clinicaltrials.gov) - May 30, 2022
P1, N=140, Not yet recruiting, Sponsor: Novartis Pharmaceuticals